22nd Century Group, Inc.

Company overview

22nd Century Group, Inc. is a Nevada corporation operating in the tobacco products sector. Its primary business is the manufacture and distribution of VLN cigarettes (cigarettes with 95% less nicotine) and turnkey contract manufacturing of cigarettes and filtered cigars for established tobacco brands. The company is expanding into a broader Reduced Nicotine Content (RNC) category and pursuing cross-branding opportunities through contract manufacturing relationships.

Key products and regulatory status

• VLN cigarettes: approximately 95% less nicotine than traditional cigarettes; marketed under Modified Risk Tobacco Product (MRTP) authority.
• Regulatory actions:
  • Initial FDA PMTA marketing order in 2019 for the RNC cigarette line.
  • MRTP marketing orders issued in December 2021 for VLN King and VLN Menthol King (95% reduced nicotine).
• Authorized MRTP marketing claims include "95% less nicotine," "Helps reduce your nicotine consumption," and "Greatly reduces your nicotine consumption." These claims must be accompanied by the statement "Helps You Smoke Less."
• The category remains subject to FDA activity, including a 2025 NPRM proposing a maximum nicotine content standard and ongoing oversight of MRTPs and other potential regulatory changes (for example, nicotine standards and menthol/flavor rules).

Manufacturing, facilities, and capacity

• Owns and operates a 60,000 sq. ft. manufacturing facility in Mocksville, North Carolina, through NASCO Products, LLC, a wholly owned subsidiary.
• Production capacity exceeds 45 million cartons of combusted tobacco products annually.
• Facility is designed for high-speed, automated, vertically integrated production.
• Operates under the Master Settlement Agreement framework as a Subsequent Participating Manufacturer (SPM) following the NASCO acquisition in 2014.

Corporate and operating structure

• NASCO Products, LLC is the federally licensed tobacco product manufacturer and the operating arm for production.
• The company holds rights to proprietary, non-GMO low-nicotine tobacco blends licensed from North Carolina State University (NCSU) and the University of Kentucky, used to produce RNC cigarettes.
• R&D has historically used exclusive licenses and collaborations with NCSU and the University of Kentucky, with ongoing efforts to expand non-GMO low-nicotine tobacco lines.

Research, development, and intellectual property

• Maintains an extensive patent portfolio and exclusive worldwide licenses related to altered nicotine content in tobacco plants.
• Technologies focus on regulating nicotine biosynthesis in tobacco plants; non-GMO approaches have been developed for broader markets.
• Protection also includes trade secrets and registered trademarks.
• Licensing arrangements with third parties are important for access to essential IP; those licenses may be maintained, enforced, or renegotiated by licensors.

Market presence, customers, and distribution

• Pilot VLN program launched in 2022 and expanded in 2023 to more than 5,000 stores across 26 states.
• Strategy shifted in 2025 to produce VLN versions of popular cigarette brand lines for existing clients, distributed through those clients' channels, using contract manufacturing relationships and cross-branding opportunities.
• Initial distribution focus is convenience stores, with emphasis on rate-of-sale, branding, packaging, and messaging to drive adult smoker adoption.
• Market opportunity cited at roughly 270,000 domestic tobacco retail outlets and a substantial portion of the U.S. $58 billion combustible cigarette market.

Employees and financial position

• Employees: 32 as of December 31, 2025 (all based in the United States).
• Cash position: approximately $3.8 million in cash and cash equivalents as of March 20, 2026.
• The company reports a history of losses and negative cash flows, indicating ongoing operating losses and a going-concern risk.

Geographic and regulatory footprint

• Primary operations located in the United States (Mocksville, North Carolina facility); distribution through retailers and contract manufacturing for domestic and international brands.
• Regulatory environment includes FDA oversight under the Tobacco Control Act (premarket review, MRTP and PMTA processes, post-market reporting), state and local regulations, and environmental compliance.
• Potential international expansion requires separate regulatory authorizations, which can be lengthy and costly.

Intellectual property protection and risks

• Relies on patents, exclusive licenses, and trade secrets to protect low-nicotine tobacco technologies.
• Patent coverage includes nicotine biosynthesis control and non-GMO approaches; some patents expire in the coming years while others extend further.
• Dependence on third-party licenses carries risk if licensors fail to maintain patents or enforce rights, or if third parties develop competing or blocking technologies.

Strategic points

• Positions VLN cigarettes as a combustible alternative for adult smokers seeking to reduce nicotine intake, promoted under a "Take Control" message.
• Business model combines in-house manufacturing with an emphasis on contract manufacturing for third-party brands, enabling cross-sale opportunities and broader distribution.
• Future performance depends on continued regulatory approvals, market adoption of MRTP-reduced nicotine products, and the ability to scale manufacturing and distribution to meet demand.